A Risk-Benefit Assessment of Pharmacotherapy for Anxiety Disorders in Children and Adolescents

ISSN： 0114-5916

Source： Drug Safety, Vol.19, Iss.4, 1998-10, pp. : 283-297

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Risk-Benefit Assessment of Pharmacotherapies for Clinical Depression in Children and Adolescents

By Renaud J. Axelson D. Birmaher B.

Drug Safety, Vol. 20, Iss. 1, 1999-01 ,pp. : 59-75

Adis International

Access to resources Recommend Favorite

Benefit-Risk Assessment of Atypical Antipsychotics in the Treatment of Schizophrenia and Comorbid Disorders in Children and Adolescents

By Paz Toren Sharon Ratner Nathaniel Laor Abraham Weizman

Drug Safety, Vol. 27, Iss. 14, 2004-01 ,pp. : 1135-1156

Adis International

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Intra-Articular Corticosteroids in Rheumatic Disorders

By Hunter J.A. Blyth T.H.

Drug Safety, Vol. 21, Iss. 5, 1999-11 ,pp. : 353-365

Adis International

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Abciximab in Angioplasty

By Kleiman N.S.

Drug Safety, Vol. 20, Iss. 1, 1999-01 ,pp. : 43-57

Adis International

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Amifostine in Cytoprotection

By Mabro M.

Drug Safety, Vol. 21, Iss. 5, 1999-11 ,pp. : 367-387

Adis International

Access to resources Recommend Favorite